Coronavirus disease 2019 (COVID-19) remains an increasing global pandemic, with significant morbidity and mortality. Severe complications of COVID-19 associated with coagulation changes, mainly characterized by increased D-dimer and fibrinogen levels with higher thrombosis risk, in particular pulmonary embolism (PE), have been reported recently \[[@CR1]\]. However, the epidemiology of PE among COVID-19 patients is currently only based on small case series and retrospective studies. This systematic review and meta-analysis addresses this gap in knowledge, facilitating first-line healthcare providers' understanding of PE incidence and mortality in COVID-19.

Relevant Chinese or English language studies were identified by systematic search of EMBASE and PUBMED from inception to June 28, 2020, using the keywords "COVID-19," "pulmonary embolism," "incidence," "prevalence," and "mortality" with appropriate MeSH terms, whereby the reference lists of identified studies yielded additional sources. We excluded conference abstracts, other types of publications (e.g., editorials, review articles, commentaries and treatment consensus), and studies lacking PE incidence or mortality rate reports. Two reviewers (SCL, SCS) screened the titles and abstracts for relevance, independently assessed the full texts of the screened search results, and drew up a final list of studies for inclusion through discussion and only after reaching full agreement. All statistical analyses were performed using MedCalc (Windows) version 15.0 (MedCalc Software, Ostend, Belgium). Incidence and mortality rates of PE in COVID-19 are represented as proportions with 95% confidence interval (CI), using the random effects model, and displayed as Forest plot. Heterogeneity among the studies was detected by Cochran *Q* test, whereby a *p* value \< 0.10 indicated significant heterogeneity. We assessed the proportion of variation in study estimates attributable to heterogeneity through the *I*^2^ statistic.

We excluded 78 out of 97 articles screened: 20 studies were duplicates, 5 were irrelevant, 3 were conference abstracts, 21 were other types of publications, 28 lacked data on PE incidence or mortality, and 1 was published in French. Ultimately, our analysis included 19 articles, mostly from Europe (84%), and we summarize their demographic data in Table [1](#Tab1){ref-type="table"}. Overall, the incidence and mortality rate of COVID-19 patients developing PE was 15.3% (95%: 9.8--21.9) and 45.1% (95%: 22.0--69.4), respectively. Some evidence of statistical heterogeneity among the studies reporting PE incidence (*I*^2^: 92.0%, *p* \< 0.001) and mortality (*I*^2^: 78.6%, *p* \< 0.001) in COVID-19 was observed (Fig. [1](#Fig1){ref-type="fig"}). Table 1Study characteristicsFirst author (Year)Study designCity (country)Male (%)Age (median, years)SettingsPE diagnosisD-dimer (median, mg/dL)Prophylactic anticoagulation (%)Mechanical ventilation (%)ARDS (%)Overall mortality (%)***Asia*** Wang Y (2020) \[[@CR2]\]RCT (remdesivir group)Beijing (China)5666InpatientNANANA71015 Wang Y (2020) \[[@CR2]\]RCT (placebo group)Beijing (China)6564InpatientNANANA13813***America*** Riker RR (2020) \[[@CR3]\]Case seriesPortland (USA)NANAInpatient (ICU)CTPANANA100100NA LeBrun DG (2020) \[[@CR4]\]Retrospective cohortNew York (USA)3387\*Inpatient (ICU, ward)NANANA33NA56***Europe*** Wichmann D (2020) \[[@CR5]\]Case seriesHamburg (Germany)7573MortuaryAutopsy90.43333NA100 Klok FA (2020) \[[@CR6]\]Retrospective cohortLeiden (Netherlands)7664\*Inpatient (ICU)CTPANA100NANA22 Llitjos JF (2020) \[[@CR7]\]Retrospective cohortPairs (France)7768Inpatient (ICU)CDU1.8311008112 Helms J (2020) \[[@CR8]\]Prospective cohortStrasbourg (France)8163Inpatient (ICU)CTPA2.31001001009 Menter T (2020) \[[@CR9]\]Retrospective cohortBasel (Switzerland)8176\*MortuaryAutopsy4.0NA30NA100 Florian Bompard (2020) \[[@CR10]\]Retrospective cohortParis (France)7064Inpatient, outpatientCTPA1.65313NA12 Hékimian G (2020) \[[@CR11]\]Retrospective cohortParis (France)NANAInpatient (ICU)CTPA or autopsyNANANANANA Artifoni M (2020) \[[@CR12]\]Retrospective cohortNantes (France)6164Inpatient (ICU, ward)CTPA0.89911NANA Fraissé M (2020) \[[@CR13]\]Retrospective cohortArgenteuil (France)7961Inpatient (ICU)CDU2.44789NA41 Thomas W (2020) \[[@CR14]\]Retrospective cohortCambridge (UK)6920--29: 2%30--39: 5%40--49: 13%50--59: 29%60--69: 22%70--79: 27%80--89: 3%Inpatient (ICU)CTPA0.4NA83NA16 Lodigiani C (2020) \[[@CR15]\]Retrospective cohortMilano (Italy)6866Inpatient (ICU, ward)CTPASurvivors:Day 1--3: 0.4Day 4--6: 0.4Day 7--9: 0.5Non-survivors:Day 1--3: 0.9Day 4--6: 0.9Day 7--9: 1.579NANA26 Poissy J (2020) \[[@CR16]\]Case seriesLille (France)NANAInpatient (ICU)CTPANANA636314 Gervaise A (2020) \[[@CR17]\]Retrospective cohortSaint Mande Cedex (France)7562\*OutpatientCTPA3.6\*NA57NA15 Longchamp A (2020) \[[@CR18]\]Case seriesSion (Switzerland)6468\*InpatientCTPA2.19692NA20 Leonard-Lorant I (2020) \[[@CR19]\]Retrospective cohortStrasbourg (France)6664Inpatient (ICU, ward)CTPAPE: 15.4Non-PE: 1.946NANANA Grillet F (2020) \[[@CR20]\]Retrospective cohortBesancon (France)7066\*Inpatient (ICU, ward)CTPANANA34NANA\*In studies not reporting the median, results are represented by the mean*CDU* complete duplex ultrasound, *CTPA* CT pulmonary angiography, *ICU* intensive care unit, *NA* not available, *PE* pulmonary embolism, *RCT* randomized controlled trialFig. 1Forest plot of PE incidence and mortality in COVID-19 infections from included studies. **a** PE incidence in COVID-19 infections. **b** PE mortality in COVID-19 infections

With increasing reports of PE following COVID-19 infection, our findings indicate that nearly 2 in 10 developed PE among a total of 1835 COVID-19 patients. Immobilization, inflammation, activated coagulation, and suppressed fibrinolysis have been proposed to explain the occurrence of PE in COVID-19 patients; however, the incidence of PE in COVID-19 patients is higher than in patients with seasonal and pandemic influenza (3%) \[[@CR21]\]. In addition, our report indicates COVID-19 patients with PE may have up to 45% higher mortality rate compared to general cases (in-hospital mortality rate 4%) \[[@CR22]\]. Therefore, first-line healthcare providers should be vigilant about the occurrence of severe and potentially fatal PE complications in COVID-19 patients \[[@CR23]\].

As far as we know, this systematic review is the first summarizing PE incidence and mortality in COVID-19 patients. However, caution is advised in interpreting our findings. First, most published literatures are observational studies, making it difficult to confirm causality between COVID-19 and PE. Second, clinical heterogeneity between studies is noteworthy; for example, the included studies apply different diagnostic tools of varying sensitivity and specificity to investigate PE incidence. In conclusion, prevention and control of COVID-19 remains paramount in the current pandemic, but repeated assessment and optimal management of PE complications may significantly modify the prognosis and reduce mortality in patients with COVID-19 \[[@CR24]\].
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